CN119144525B - Bacillus for producing moisturizing anti-inflammatory polysaccharide and application thereof - Google Patents
Bacillus for producing moisturizing anti-inflammatory polysaccharide and application thereof Download PDFInfo
- Publication number
- CN119144525B CN119144525B CN202411651132.0A CN202411651132A CN119144525B CN 119144525 B CN119144525 B CN 119144525B CN 202411651132 A CN202411651132 A CN 202411651132A CN 119144525 B CN119144525 B CN 119144525B
- Authority
- CN
- China
- Prior art keywords
- bacillus
- culture
- inflammatory
- fermentation
- polysaccharide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229920001282 polysaccharide Polymers 0.000 title claims abstract description 61
- 150000004676 glycans Chemical class 0.000 title claims abstract description 60
- 239000005017 polysaccharide Substances 0.000 title claims abstract description 60
- 230000003110 anti-inflammatory effect Effects 0.000 title claims abstract description 24
- 230000003020 moisturizing effect Effects 0.000 title claims abstract description 19
- 241000193830 Bacillus <bacterium> Species 0.000 title claims abstract description 18
- 241000194110 Bacillus sp. (in: Bacteria) Species 0.000 claims abstract description 27
- 239000001963 growth medium Substances 0.000 claims abstract description 17
- 239000003814 drug Substances 0.000 claims abstract description 8
- 239000002537 cosmetic Substances 0.000 claims abstract description 4
- 238000004519 manufacturing process Methods 0.000 claims abstract description 4
- 229940079593 drug Drugs 0.000 claims abstract description 3
- 238000000855 fermentation Methods 0.000 claims description 35
- 230000004151 fermentation Effects 0.000 claims description 35
- 238000000034 method Methods 0.000 claims description 16
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 15
- 239000001301 oxygen Substances 0.000 claims description 15
- 229910052760 oxygen Inorganic materials 0.000 claims description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 14
- 229920002444 Exopolysaccharide Polymers 0.000 claims description 11
- 239000012137 tryptone Substances 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 9
- 229940041514 candida albicans extract Drugs 0.000 claims description 9
- 238000011218 seed culture Methods 0.000 claims description 9
- 239000012138 yeast extract Substances 0.000 claims description 9
- 239000002609 medium Substances 0.000 claims description 8
- 238000001914 filtration Methods 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- 239000011780 sodium chloride Substances 0.000 claims description 7
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 6
- 229930006000 Sucrose Natural products 0.000 claims description 6
- 238000012258 culturing Methods 0.000 claims description 6
- 239000012528 membrane Substances 0.000 claims description 6
- 238000000746 purification Methods 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- 239000005720 sucrose Substances 0.000 claims description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 5
- 238000009630 liquid culture Methods 0.000 claims description 5
- 229920001817 Agar Polymers 0.000 claims description 3
- 239000008272 agar Substances 0.000 claims description 3
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 238000009423 ventilation Methods 0.000 claims description 3
- 241000894006 Bacteria Species 0.000 claims description 2
- 238000005119 centrifugation Methods 0.000 claims description 2
- 230000002906 microbiologic effect Effects 0.000 claims description 2
- 238000009629 microbiological culture Methods 0.000 claims description 2
- 239000005909 Kieselgur Substances 0.000 claims 1
- 102000004142 Trypsin Human genes 0.000 claims 1
- 108090000631 Trypsin Proteins 0.000 claims 1
- 239000012588 trypsin Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 8
- 230000000813 microbial effect Effects 0.000 abstract description 4
- 239000000243 solution Substances 0.000 description 27
- 238000012360 testing method Methods 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 14
- 108090001005 Interleukin-6 Proteins 0.000 description 9
- 102000004889 Interleukin-6 Human genes 0.000 description 9
- 239000013642 negative control Substances 0.000 description 8
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 7
- 101000845170 Homo sapiens Thymic stromal lymphopoietin Proteins 0.000 description 7
- 102100031294 Thymic stromal lymphopoietin Human genes 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 229920002674 hyaluronan Polymers 0.000 description 7
- 229960003160 hyaluronic acid Drugs 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 6
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 6
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 6
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 6
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 5
- 230000014759 maintenance of location Effects 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 239000002689 soil Substances 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241001052560 Thallis Species 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 238000005273 aeration Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- MYKOKMFESWKQRX-UHFFFAOYSA-N 10h-anthracen-9-one;sulfuric acid Chemical compound OS(O)(=O)=O.C1=CC=C2C(=O)C3=CC=CC=C3CC2=C1 MYKOKMFESWKQRX-UHFFFAOYSA-N 0.000 description 2
- 108020004465 16S ribosomal RNA Proteins 0.000 description 2
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000194105 Paenibacillus polymyxa Species 0.000 description 2
- 229920002385 Sodium hyaluronate Polymers 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000009776 industrial production Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 229940010747 sodium hyaluronate Drugs 0.000 description 2
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 239000002028 Biomass Substances 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- -1 PGE-2 Proteins 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical class N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000003746 surface roughness Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0003—General processes for their isolation or fractionation, e.g. purification or extraction from biomass
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/85—Products or compounds obtained by fermentation, e.g. yoghurt, beer, wine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/07—Bacillus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Birds (AREA)
- Mycology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Polymers & Plastics (AREA)
- Rheumatology (AREA)
- Materials Engineering (AREA)
- Pain & Pain Management (AREA)
- Sustainable Development (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种产保湿抗炎多糖的芽孢杆菌及其应用，涉及微生物技术领域。本发明公开的芽孢杆菌Bacillus sp.ZR001生产的胞外多糖具有皮肤保湿和抗炎的作用，能广泛应用于药品、化妆品和护肤品领域，本发明还公开了一种应用芽孢杆菌Bacillus sp. ZR001生产胞外多糖的方法，通过优化芽孢杆菌Bacillus sp. ZR001培养基和培养条件，胞外多糖的产量极大提高，最高可达25.8g/L。
The invention discloses a bacillus producing moisturizing and anti-inflammatory polysaccharides and its application, and relates to the field of microbial technology. The extracellular polysaccharide produced by the bacillus sp. ZR001 disclosed in the invention has the effects of moisturizing the skin and anti-inflammatory, and can be widely used in the fields of medicines, cosmetics and skin care products. The invention also discloses a method for producing extracellular polysaccharides by using the bacillus sp. ZR001. By optimizing the culture medium and culture conditions of the bacillus sp. ZR001, the yield of the extracellular polysaccharide is greatly improved, and can reach up to 25.8 g/L at the highest.
Description
Technical Field
The invention relates to the technical field of microorganisms, in particular to bacillus for producing moisturizing anti-inflammatory polysaccharide and application thereof.
Background
Polysaccharide is a natural polymer formed by connecting a plurality of monosaccharides through glycosidic bonds, and is widely found in plants, animals and microorganisms, and （Zong A, Cao H, Wang F. Anticancer polysaccharides from natural resources: A review of recent research[J]. Carbohydrate Polymers, 2012, 90(4): 1395-1410）. among microbial polysaccharides, most of polysaccharide derived from bacteria is released into extracellular medium, so that it is classified as EPS type （Sutherland I W. Novel and established applications of microbial polysaccharides[J]. Trends in Biotechnology, 1998, 16(1): 41-46）., and bacterial extracellular polysaccharide exhibits a wide range of biological activities such as antibacterial, antiviral, antioxidant, anti-inflammatory, antitumor, immunomodulating, hypoglycemic and the like in-vivo and in-vitro studies. Compared with plant polysaccharide and animal polysaccharide, the bacterial EPS has the advantages of low production cost, no influence of factors such as geographical environment, climate, natural disasters and the like, stable quality and yield, easy extraction, realization of large-scale industrial production by submerged fermentation and the like (Guo Min. Research progress of microbial fermentation for producing polysaccharide [ J ]. Microbiological report, 2008, 35 (7): 1084-1090), and has excellent application prospect in the fields of biological materials, pharmacy, food and the like.
The application of the bacillus extracellular polysaccharide is concentrated in the fields of biological medicine and ecological agriculture at present, and the researches of few applications in the field of daily chemicals, wang and the like prove that the bacillus polymyxa extracellular polysaccharide can repair cells damaged by ultraviolet rays, provide a new thought for developing novel ultraviolet damage repairing agents, and do not see the research of applying the bacillus polymyxa extracellular polysaccharide to the aspects of skin moisturizing and anti-inflammatory.
Disclosure of Invention
Aiming at the defects of the prior art, the invention provides Bacillus sp for producing moisturizing anti-inflammatory polysaccharide and application thereof.
The invention is as follows:
The invention provides Bacillus for producing moisturizing anti-inflammatory polysaccharide, which is Bacillus sp.ZR001, is isolated from soil of half mu flower field gella rosebase (36 DEG 12 '00' N, 117 DEG 42 '00.00' E) in Jinan, shandong province, is identified as Bacillus sp through 16S rDNA strain identification, the nucleotide sequence of the 16S rDNA is shown as SEQ ID NO.1, and the Bacillus is preserved in China general microbiological culture collection center with the preservation number of CGMCC No. 32048 and the preservation date of 2024, 9 and 23 days.
In a second aspect, the invention provides an extracellular polysaccharide produced by the Bacillus sp.
In a third aspect the invention provides a composition, the composition comprises the Bacillus Bacillus sp. Or said exopolysaccharide.
In a fourth aspect the invention provides the use of said Bacillus sp or said extracellular polysaccharide or said composition for moisturizing and/or anti-inflammatory.
In a fifth aspect, the invention provides the use of said Bacillus sp or said extracellular polysaccharide or said composition for the preparation of a pharmaceutical, cosmetic, skin care product. Preferably, the medicament is an anti-inflammatory medicament.
In a sixth aspect, the invention provides a method for culturing said Bacillus sp, under the culture conditions:
Shake flask seed culture, namely inoculating a single colony (or a glycerol tube) into a 250 ml triangular shake flask with a liquid loading amount of 50 ml seed culture medium, culturing for 18-24 hours at 25-35 ℃ at 150-250 rpm;
The culture condition of the seed tank is that the temperature is 25-35 ℃, the aeration rate is 800-1200L/h, the rotating speed is 300-350 rpm, and the culture period is 20-28 hours;
the culture conditions of the fermentation tank are that the temperature is 25-35 ℃, the ventilation rate is 800-1200L/h, and the rotating speed is 100-rpm. When dissolved oxygen rises back, sucrose and tryptone are added, and the dissolved oxygen is controlled to be 30-60% by adjusting the feeding rate and the rotating speed, and the culture period is 40-56 hours.
Further, the seed culture medium comprises a solid culture medium and a liquid culture medium, wherein the solid culture medium comprises 8-13g/L of tryptone, 4-7 g/L of yeast extract, 8-13g/L of sodium chloride and 15-25 g/L of agar, and the liquid culture medium comprises 8-13g/L of tryptone, 4-7 g/L of yeast extract and 8-13g/L of sodium chloride.
Further, the fermentation medium comprises 40-60g/L of sucrose, 4-6g/L of tryptone, 0.5-1.5 g/L of yeast extract powder and 2-5g/L of disodium hydrogen phosphate.
In a seventh aspect, the present invention provides a method of producing an extracellular polysaccharide, the method comprising the steps of:
1) And in the fermentation stage of Bacillus, inoculating the seed liquid of the cultured Bacillus sp.ZR001 into a fermentation tank according to the inoculation amount of 1-5%, and the temperature is 25-35 ℃. When the dissolved oxygen rises, the dissolved oxygen is controlled to be 30-60% by adjusting the feeding rate and the rotating speed, and the culture period is 36-60 hours.
2) And a purification stage, namely placing the culture solution obtained in the step 1) in a tank, centrifuging the fermentation liquor by using a tubular centrifuge 13000-15000 rpm/min to remove thalli, adding diatomite into the centrifuged liquor, filtering by using a plate frame, and filtering by using a 0.45um filter membrane to obtain a polysaccharide solution.
In a specific embodiment of the invention, the method for producing exopolysaccharide comprises the steps of:
1) And in the Bacillus fermentation stage, the cultured Bacillus sp.ZR001 seed solution is inoculated into a fermentation tank according to the inoculation amount of 2 percent, and the temperature is 30 ℃. When dissolved oxygen rises, the dissolved oxygen is controlled to be 30-60% by adjusting the feeding rate and the rotating speed, and the culture period is 48 hours;
2) And a purification stage, namely placing the culture solution obtained in the step 1) into a tank, fermenting and culturing the culture solution for 48 hours, centrifuging the fermentation solution by using a tube type centrifuge at 14000rpm/min to remove thalli, adding diatomite into the centrifuged liquid, filtering the mixture by using a plate frame, and filtering the mixture by using a 0.45um filter membrane to obtain a polysaccharide solution.
The beneficial effects of the invention include, but are not limited to:
1. The Bacillus sp.ZR001 can greatly improve the yield of extracellular polysaccharide, can reach 15.6g/L at maximum, provides a new choice for large-scale industrial production of extracellular polysaccharide, and has a far-reaching application prospect;
2. The extracellular polysaccharide produced by Bacillus sp.ZR001 has the effects of moisturizing and/or anti-inflammatory skin, and can be widely applied to the aspects of preparing medicines, cosmetics and skin care products;
3. the invention also optimizes the invention to improve the content of extracellular polysaccharide in the fermentation broth by optimizing the Bacillus sp.ZR001 fermentation medium and the culture condition, and further improves the yield of extracellular polysaccharide in the Bacillus sp.ZR001 fermentation broth by optimizing the fermentation medium and the culture condition, wherein the yield is 25.8g/L at most.
Drawings
The accompanying drawings, which are included to provide a further understanding of the invention and are incorporated in and constitute a part of this specification, illustrate embodiments of the invention and together with the description serve to explain the invention and do not constitute a limitation on the invention. In the drawings:
FIG. 1 is a flow chart of extraction of a Bacillus sp.ZR001 fermentation extracellular polysaccharide solution in an embodiment of the present invention;
FIG. 2 is a graph showing the hygroscopicity of hyaluronic acid, trehalose and Bacillus sp.ZR001 exopolysaccharide in examples of the present invention;
FIG. 3 is a schematic representation of the results of the moisturizing effect of hyaluronic acid, trehalose and Bacillus sp.ZR001 exopolysaccharide in examples of the present invention;
FIG. 4 is a graph showing the relative activity of each cell in the cytotoxicity test of the embodiment of the present invention;
FIG. 5 is a graph showing the relative concentration of IL-6 in anti-inflammatory test experiments according to the embodiments of the present invention, # represents that the differences have a statistical significance (p < 0.05) compared with the negative control group (NC), and # represents that the differences have a statistical significance (p < 0.05) compared with the model control group (M);
FIG. 6 is a graph showing the relative concentration of TNF-. Alpha.in the anti-inflammatory test of the present invention, wherein # indicates that the difference has a statistical significance (p < 0.05) compared to the negative control group (NC) and # indicates that the difference has a statistical significance (p < 0.05) compared to the model control group (M);
Fig. 7 is a graph showing the relative concentration results of TSLP in anti-inflammatory test experiments according to embodiments of the present invention, wherein # indicates that the difference has a statistical significance (p < 0.05) compared to the negative control group (NC), and # indicates that the difference has a statistical significance (p < 0.05) compared to the model control group (M).
Detailed Description
The present invention will be described in detail with reference to examples, but the present invention is not limited to these examples, and the raw materials and catalysts in the examples of the present invention are commercially available unless otherwise specified.
The concentration percentages in the present invention are mass percentages unless otherwise specified.
The instrument comprises an automatic fermentation tank 15L and 50L of Shanghai national strong biochemical equipment, a mass spectrometer of the Shanghai Shuyu Hengping process, a Biostar software package of the national biochemical engineering center, a 722 type ultraviolet visible spectrophotometer and a rotary shaking table.
EXAMPLE 1 isolation and characterization of Bacillus sp.ZR001
Bacillus sp.ZR001 is obtained by separating from soil of half mu of Huatian glas rose base (36 DEG 12 '00.00' N, 117 DEG 42 '00.00' E) in Jinan, shandong province, wherein the separation process is that about 10g of soil at a depth of 10-20 cm is selected, and 100ml of physiological saline is added for uniform mixing. Water bath was carried out at 80℃for 1h, followed by addition of 4g NaCl and 37℃for 2h. 1mL of the soil suspension is diluted by 10 times of sterile water, 100 mu L of diluted test solution is dripped on LB solid medium, smeared uniformly and cultured at the temperature of 37 ℃ in an inverted way overnight. The morphology of individual colonies on the medium, including the color, size, edge and surface roughness of the colonies, was observed to obtain 23 strains. And (3) fermenting the strains respectively, and detecting the content of extracellular polysaccharide to obtain 6 primary screening strains capable of producing extracellular polysaccharide.
The invention obtains the strain ZR001 of high-yield extracellular polysaccharide by screening a plurality of microorganisms B1, B2, B3, B4, B5 and ZR001 and respectively fermenting, and the results of extracellular polysaccharide yield after different strains are fermented for 48 hours are shown in the table 1.
TABLE 1 fermentation of strains for 48h polysaccharide yield
EXAMPLE 2 fermentation culture of Bacillus sp.ZR001 and isolation and purification of extracellular polysaccharide
Bacterial strain is obtained by natural environment screening.
The seed culture medium comprises tryptone 10.0 g, yeast extract 5.0 g, sodium chloride 10.0 g, agar 20.0 g, and 1.0 liter purified water, and sterilizing at 121deg.C for 20min to obtain seed solid culture medium. Tryptone 10.0 g, yeast extract 5.0 g, sodium chloride 10.0 g, and sterilizing at 121deg.C for 20min to obtain seed liquid culture medium.
The fermentation medium is prepared by adding sucrose 50.0 g, tryptone 5.0 g, yeast extract 1.0 g and disodium hydrogen phosphate 3.0 g into 1.0 liter of purified water, adjusting pH to 7.2, sterilizing at 115 ℃ in a sterilizing pot for 25 min.
Culture method
(1) Culture conditions
Shake flask seed culture, single colony (or glycerol tube) is inoculated into 250 ml triangle shake flask with 50ml seed culture medium, 200 rpm, 30 ℃ culture for 18-24h.
The culture condition of the seed tank is that the temperature is 30 ℃, the aeration rate is 1080L/h, the rotating speed is 300 rpm, and the culture period is 24 hours.
The culture condition of the fermentation tank is that the temperature is 30 ℃, the aeration rate is 1080L/h, the rotating speed is 100: 100 rpm. When dissolved oxygen rises back, sucrose and tryptone are added, and the dissolved oxygen is controlled to be 30-60% by adjusting the feeding rate and the rotating speed, and the culture period is 48 hours.
(2) Culture process
The Bacillus sp. Fermentation extracellular polysaccharide solution extraction flow is shown in figure 1, and the main flow comprises fermentation, centrifugation, impurity removal, membrane filtration and extracellular polysaccharide solution. The method comprises the following specific steps:
① And (3) in the fermentation stage of Bacillus sp, inoculating the cultured Bacillus sp seed solution into a fermentation tank according to the inoculation amount of 2%, wherein the temperature is 30 ℃. When dissolved oxygen rises, the dissolved oxygen is controlled to be 30-60% by adjusting the feeding rate and the rotating speed, and the culture period is 48 hours.
② And in the purification stage, fermenting and culturing for 48 hours, putting the fermentation broth into a tank, centrifuging the fermentation broth by using a tubular centrifuge at 14000rpm/min to remove thalli, adding diatomite into the centrifuged broth to remove impurities, filtering by using a plate frame, and filtering by using a 0.45um filter membrane to obtain a polysaccharide solution.
③ And (3) analyzing the polysaccharide content in the fermentation liquor, namely taking a solution filtered by a filter membrane, and detecting the polysaccharide content to be 25.8g/L by using an anthrone-sulfuric acid method.
EXAMPLE 3 efficacy identification of extracellular polysaccharide
Reducing sugar determination, namely enzyme membrane detection method of a biochemical analyzer.
Polysaccharide determination, namely an alcohol precipitation method and an anthrone-sulfuric acid method.
Biomass measurement, namely, adopting a wet volume method for offline measurement, diluting fermentation liquor by a certain multiple, and measuring absorbance on a spectrophotometer to obtain an OD value.
And (3) carrying out online measurement on pH and DO by adopting a Mettler Toledo high-temperature resistant electrode.
Temperature platinum temperature electrode on-line measurement.
And (3) measuring oxygen and carbon dioxide in the inlet gas and the tail gas, namely carrying out real-time online acquisition and analysis on the inlet gas and the tail gas in the fermentation process by adopting a mass spectrum MAX300-LG in the process of Extrel in the United states.
(1) Moisture retention test experiment
And (3) performing vacuum freeze drying on the ZR001 extracellular polysaccharide solution after fermentation and purification to obtain polysaccharide powder. With reference to the moisture absorption and retention test method, experiments were performed using 912 and 914 batches of polysaccharide powder.
Hygroscopicity test A lyophilized sample of extracellular polysaccharide was precisely weighed, dried to constant mass of trehalose and sodium hyaluronate (Hua Xi organisms, name: sodium hyaluronate (HA-TP), lot number: J201230575) each 0.3. 0.3 g, placed in a drying plate, placed in a 20℃thermostatted dryer with a suitable amount of saturated ammonium sulfate solution (81% relative humidity) and the mass of the sample was measured at regular time. Each sample of each group was run in 3 replicates. The calculation formula of the sample moisture absorption rate is as follows:
Moisture absorption rate ×100%
Wherein m t is the mass of the sample at t time, the unit is g, and m 0 is the mass of the dry sample, the unit is g.
And (3) a moisture retention test, namely precisely weighing a freeze-dried sample of extracellular polysaccharide, drying to constant weight of trehalose and hyaluronic acid respectively at 0.3-g, adding 3 times of deionized water, uniformly and completely soaking the sample, placing the sample in a dryer containing dry silica gel (relative humidity is 0%), and weighing the mass of the sample at regular time. The sample moisture retention was calculated as follows:
Moisture retention = ×100%
Wherein m t is the mass of the sample at t time, m 0 is the mass of the dry sample, m Water and its preparation method is the mass of the added deionized water, and the unit is g.
The results are shown in FIGS. 2-3. The moisturizing rate of hyaluronic acid, trehalose and extracellular polysaccharide produced by the strain ZR001 is reduced along with the extension of time in a dry environment, and in 60 h, the moisturizing rate of extracellular polysaccharide produced by the strain ZR001 is better than that of hyaluronic acid and chitosan, and in 60 h, the moisturizing rate of extracellular polysaccharide produced by the strain ZR001 is 51 percent, equivalent to that of hyaluronic acid and better than that of trehalose, and after 60 h, the moisturizing rate of hyaluronic acid is higher than that of extracellular polysaccharide produced by the strain ZR001, so that the extracellular polysaccharide has a certain moisturizing effect.
(2) Anti-inflammatory test experiments
Experimental principle:
Inflammation is one of the most common conditions in the clinic, a defensive response of the human body to ensure removal of harmful stimuli and repair of damaged tissues. When human immune cells are subjected to inflammatory factors, some small molecular weight soluble proteins or polypeptides which can transmit information among cells and have specific immunoregulatory functions are secreted by the body itself and can participate in or cause inflammatory reactions, and these substances are called inflammatory factors and include NO, TNF-alpha, IL-6, PGE-2, IL-1 and the like. NO, IL-6 and TNF-alpha are important cytokines in inflammatory reactions, and they have direct or indirect effects on cellular inflammation and influence each other.
In the experiment, by using LPS-induced RAW264.7 cells (cell line: RAW264.7 cells, source: north Nabiological, passage number: 8) as an in vitro inflammatory cell model, inflammatory factors IL-6, TNF-alpha and TSLP secreted in cell supernatant are detected by ELISA kit, so as to evaluate the anti-inflammatory effect of a sample to be tested.
The experimental steps are as follows:
1. Cytotoxicity screening
1.1 Cultured cells were seeded in 96-well plates and placed in an incubator for 18-24 h to 80% confluence of cells.
1.2 Removing the original culture solution, adding 100 mu L of extracellular polysaccharide diluent of samples with different concentrations into each hole, exposing 24+/-0.5 h in an incubator, wherein the concentrations of the samples are respectively 20%, 6%, 2%, 0.6%, 0.2%, 0.06%, 0.02% and 0.006%, only adding the culture solution with the same volume into a negative control group (NC), adding the culture solution into a model control group (M) and performing LPS induction, adding the culture solution containing samples with different concentrations into a sample group (TA) to be detected and performing LPS induction, and adding the culture solution containing dexamethasone into a positive control group (PC) and performing LPS induction.
1.3 Wells were added 20. Mu.L MTT solution and incubated at 37℃3.+ -. 0.5 h. The MTT solution was then removed, 100. Mu.L of DMSO was added to each well, and absorbance was measured at 570 nm wavelength after shaking 10-15min in the dark.
Cell activity was calculated for each group based on the negative Control (Control) cell activity as 100% (Viability). The calculation formula is as follows:
Wherein, OD TA is the absorbance value measured at 570-nm wavelength of the sample group to be tested, OD Blank is the absorbance value measured at 570-nm wavelength of the negative control group (NC), and OD Control is the absorbance value measured at 570-nm wavelength of the model control group (M).
As shown in FIG. 4, according to the results of the cell activity test, the concentration of the sample below 0.6% has less influence on the cell activity, and 0.60% (v/v), 0.10% (v/v) and 0.01% (v/v) are selected as the test concentrations of the subsequent efficacy experiments for more intuitively displaying the test results and facilitating the experimental operation.
2. Cell anti-inflammatory test
2.1 Conventional cell culture, cell suspension was inoculated into 12-well cell culture plates and returned to the incubator for culture 18-24 h.
2.2 Removing the culture plates, discarding the original culture solution in the wells, adding test samples with concentration of 0.6%, 0.1% and 0.01% of culture solution of LPS in each well, adding the culture solution of LPS as a stimulator in the model group (M), adding the culture solution of dexamethasone and LPS in the positive control group (PC), adding the culture solution in the negative control group (NC), and culturing 24+ -1 h.
2.3 Collecting supernatant, preserving at-80 ℃, and measuring cytokine by ELISA kit (Wuhan Huamei: CSB-E04639 m).
The data were analyzed using SPSS and expressed as mean ± standard deviation, if p <0.05 considered differences were statistically significant.
IL-6, TNF- α, TSLP levels were calculated as 100% for model control group (M) and relative amounts of each group were calculated.
The results are shown in FIGS. 5-7, and the relative content of IL-6, TNF-alpha and TSLP is obviously increased (p < 0.05) in the model group (M) compared with the negative control group (NC) under the cell anti-inflammatory test condition, and the relative content of IL-6, TNF-alpha and TSLP is obviously reduced (p < 0.05) in the positive control group compared with the model group, so that the modeling is successful. Sample "strain ZR001 produced exopolysaccharide" showed 42%, 22%, 18% decrease in IL-6 relative content, 55%, 50%, 39% decrease in TNF- α relative content, 43%, 39%, 36% decrease in TSLP relative content, respectively, and significant differences (p < 0.05) compared to model group at 0.60% (v/v), 0.10% (v/v), 0.01% (v/v) test concentrations.
Under the test condition, the sample 'bacterial strain ZR001 exopolysaccharide' has anti-inflammatory effect at the test concentration of 0.60% (v/v), 0.10% (v/v) and 0.01% (v/v) under the test indexes of IL-6, TNF-alpha and TSLP.
The above description is only an example of the present invention, and the scope of the present invention is not limited to the specific examples, but is defined by the claims of the present invention. Various modifications and variations of the present invention will be apparent to those skilled in the art. Any modification, equivalent replacement, improvement, etc. made within the technical idea and principle of the present invention should be included in the protection scope of the present invention.
Claims (10)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202411651132.0A CN119144525B (en) | 2024-11-19 | 2024-11-19 | Bacillus for producing moisturizing anti-inflammatory polysaccharide and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202411651132.0A CN119144525B (en) | 2024-11-19 | 2024-11-19 | Bacillus for producing moisturizing anti-inflammatory polysaccharide and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN119144525A CN119144525A (en) | 2024-12-17 |
| CN119144525B true CN119144525B (en) | 2025-01-28 |
Family
ID=93803992
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202411651132.0A Active CN119144525B (en) | 2024-11-19 | 2024-11-19 | Bacillus for producing moisturizing anti-inflammatory polysaccharide and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN119144525B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112274528A (en) * | 2020-08-28 | 2021-01-29 | 中国科学院海洋研究所 | Application of a marine bacillus exopolysaccharide in the preparation of anti-inflammatory drugs |
| CN114058534A (en) * | 2021-10-08 | 2022-02-18 | 沈阳农业大学 | A high-yield Bacillus subtilis strain resistant to hepatocellular carcinoma exopolysaccharide and its application |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103751034A (en) * | 2014-02-12 | 2014-04-30 | 江南大学 | Application of bacillus mucilaginosus exopolysaccharide to cosmetics |
| KR102044153B1 (en) * | 2018-07-06 | 2019-11-13 | (주)바이오일레븐 | the noble Bacillus licheniformis strain and process of manufacturing of immune exopolysaccharide thereof |
| CN111961617B (en) * | 2020-08-13 | 2022-07-05 | 中国农业大学 | Multi-effect bacillus subtilis for high yield of immune polysaccharide and bacteriocin and application thereof |
-
2024
- 2024-11-19 CN CN202411651132.0A patent/CN119144525B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112274528A (en) * | 2020-08-28 | 2021-01-29 | 中国科学院海洋研究所 | Application of a marine bacillus exopolysaccharide in the preparation of anti-inflammatory drugs |
| CN114058534A (en) * | 2021-10-08 | 2022-02-18 | 沈阳农业大学 | A high-yield Bacillus subtilis strain resistant to hepatocellular carcinoma exopolysaccharide and its application |
Also Published As
| Publication number | Publication date |
|---|---|
| CN119144525A (en) | 2024-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109880758B (en) | Lactobacillus plantarum mutant strain and mutation method and application thereof | |
| CN113755544B (en) | Schizophyllum commune fermentation product, and preparation method and application thereof | |
| CN102586151B (en) | High-yield polysaccharide strain and method for producing polysaccharide by utilizing strain through fermentation | |
| CN115141760A (en) | Inonotus obliquus fermentation extract, preparation method thereof and application thereof in preparation of cosmetics | |
| CN112646849A (en) | Preparation method of microbial source chitosan oligosaccharide | |
| CN112011478A (en) | A kind of Dendrobium endophytic Gladiolus Burkholderia BL-HTie-5 and its application | |
| CN109294961B (en) | A biocontrol strain PNC25 against litchi frost blight and its application | |
| CN113957024B (en) | Rhizobium GL-1803 and application thereof in preparation of insoluble beta-glucan | |
| CN108486002B (en) | An endophyte strain of Luo Han Guo producing exopolysaccharide, method for producing exopolysaccharide and application of exopolysaccharide | |
| CN108203729B (en) | Preparation method of kelp antioxidant peptide | |
| CN111909881B (en) | A strain of Bacillus pumilus capable of producing ferulic acid esterase and its application | |
| CN119144525B (en) | Bacillus for producing moisturizing anti-inflammatory polysaccharide and application thereof | |
| CN114292763A (en) | Saccharomyces cerevisiae capable of highly producing gamma-aminobutyric acid and soluble beta-glucan and application thereof | |
| CN110616150B (en) | High-yield polysaccharide eupatorium adenophorum endophytic fungus and application thereof | |
| CN110804566B (en) | Bacillus for preventing and treating root rot of paris polyphylla and preparation method and application thereof | |
| WO2021093425A1 (en) | Root of membranous milkvetch-paecilomyces cicadae fermentative bacterium fermentation substance and application thereof | |
| CN109810918B (en) | Bacillus atrophaeus with effect of preventing wolfberry leaf blight, biological agent and application of biological agent | |
| CN105624067B (en) | Marine bacterium Pseudomonas sp SC127 and ulva sulfate rhamnosidase prepared by same | |
| CN105838625B (en) | Preparation method of a strain of Cordyceps sinensis and Cordyceps sinensis mycelium powder | |
| CN100390295C (en) | A kind of microbial polysaccharide and its production method and application | |
| CN116694485B (en) | Application of colletotrichum gloeosporioides and extracellular polysaccharide thereof as plant immunity elicitor | |
| CN114134076B (en) | Bacillus licheniformis for producing extracellular polysaccharide, flocculant and application of flocculant in sewage treatment | |
| CN110591968A (en) | A kind of method for producing phospholipase D by Streptomyces cinnamonis and method for measuring phospholipase D activity | |
| CN116855392B (en) | Houttuynia cordata fermentation broth and preparation method and application thereof | |
| CN118374368B (en) | Kudriz-awamori Pichia pastoris and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |